DHGWA
TEVA icon

Dixon Hughes Goodman Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5K Hold
571
– – ﹤0.01% 614
2021
Q4 		$5K Buy
+571
New +$5.15K ﹤0.01% 561

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's TEVA Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q1 2022 at 571 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Dixon Hughes Goodman Wealth Advisors first reported a position in TEVA in Q4 2021 and has held it in 2 quarters since. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 571 shares of Teva Pharmaceuticals worth $5K as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Teva Pharmaceuticals share count unchanged in Q1 2022.
  • Teva Pharmaceuticals made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #614 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.